BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024

Rhea-AI Summary

BioSig Technologies (OTCQB: BSGM) has announced significant improvements to its balance sheet during Q2 2024. The company has successfully negotiated a reduction in accounts payable of approximately $1.5 million with multiple vendors. A major cost-saving measure includes the termination of the office lease for their former headquarters in Westport, Connecticut, effective July 15, 2024.

CEO Anthony Amato emphasized the importance of maintaining a strong and flexible balance sheet, especially in challenging market conditions. The company plans to continue working with additional vendors to further reduce payables and will update shareholders on progress. This financial restructuring is expected to provide BioSig with more flexibility in evaluating future opportunities.

Positive

• Reduction in accounts payable by approximately $1.5 million in Q2 2024
• Termination of office lease expense for former headquarters, resulting in cost savings
• Improved balance sheet flexibility for future opportunities

Negative

• Company trading on OTCQB market, indicating potential financial challenges
• Ongoing need to negotiate with vendors to reduce payables suggests financial strain

Financial Analyst

BioSig Technologies' recent announcement of a $1.5 million reduction in accounts payable during Q2 2024 is a significant step towards improving its financial health. This move, spearheaded by new management, demonstrates a proactive approach to strengthening the company's balance sheet in a challenging market environment.

The termination of the Westport, Connecticut office lease is particularly noteworthy, as it eliminates a substantial fixed cost that was set to continue until the end of 2024. This strategic decision not only contributes to immediate cost savings but also enhances the company's financial flexibility going forward.

However, it's important to note that while this $1.5 million reduction is positive, we need to consider it in the context of BioSig's overall financial position. As an OTC-traded company, BioSig likely faces ongoing challenges in terms of capital access and investor confidence. The management's focus on vendor negotiations and cost-cutting measures suggests they're addressing these challenges head-on.

Looking ahead, investors should monitor several key factors:

• The extent of further reductions in accounts payable, as the company has indicated plans to continue this process
• The impact of these cost-saving measures on BioSig's cash burn rate and runway
• Any potential effect on the company's operations, particularly in relation to its PURE EP™ Platform
• Future revenue growth and market adoption of their FDA-cleared technology

While this news is a step in the right direction, it's important for investors to maintain a balanced view. The company's ability to translate these financial improvements into sustainable growth and profitability will be important for its long-term prospects in the competitive medical technology sector.

Medical Technology Expert

BioSig's financial restructuring efforts, while important, must be viewed through the lens of their core product, the PURE EP™ Platform. This FDA 510(k) cleared non-invasive class II device represents a significant advancement in cardiac signal visualization technology. The potential impact of this technology on cardiac ablation procedures cannot be overstated.

However, the company's focus on cost-cutting and balance sheet improvement raises some questions about the current market traction of the PURE EP™ Platform. In the medical device industry, especially for novel technologies, significant investment in sales, marketing and ongoing R&D is often necessary to drive adoption and stay competitive.

The reduction in accounts payable, while financially prudent, could potentially impact these important areas if not managed carefully. It's essential to understand whether these cost-saving measures are primarily targeting non-core expenses or if they might affect the company's ability to support and expand the adoption of their technology.

On a positive note, if BioSig can successfully streamline its operations without compromising its technological edge, it could emerge as a more efficient and competitive player in the cardiac electrophysiology market. The key will be balancing financial prudence with the necessary investments to drive market penetration and technological advancement.

Investors and industry observers should closely monitor:

• Any updates on the clinical adoption rates of the PURE EP™ Platform
• Continued investment in R&D and product improvement
• Partnerships or collaborations with healthcare providers that could accelerate market adoption
• Regulatory developments that could impact the competitive landscape for cardiac signal visualization technologies

While the financial restructuring is a positive step, the true measure of BioSig's potential lies in its ability to translate its innovative technology into widespread clinical adoption and sustainable revenue growth.

Los Angeles, CA 90025, July 25, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) or (“BioSig” or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, is pleased to announce that it has successfully negotiated with multiple vendors an initial reduction in accounts payable of approximately $1.5 million during the second quarter of 2024 since new management has taken leadership.

One substantial savings recognized is for the successful termination of the office lease expense for the former headquarters in Westport, Connecticut as of July 15, 2024 which was set to end on December 31, 2024.

The Company also plans to work with additional vendors to continue this reduction going forward and will update shareholders appropriately. The reduction will profoundly impact the Company's financial standing and improve its balance sheet substantially.

BioSig’s CEO, Anthony Amato stated, “Maintaining a strong and flexible balance sheet is a priority for our new management team. In a difficult market for companies like ours, we look for other ways to help our company and its shareholders. This reduction will provide more flexibility in evaluating opportunities that arise. We appreciate the time and patience of our vendors and acknowledge their help in putting BioSig in a much better financial position."

About BioSig Technologies, Inc. (OTCQB: BSGM)

BioSig Technologies is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. By leveraging a first of its kind combination of hardware and software, we deliver unprecedented cardiac signal clarity, ending the reliance on ‘mixed signals’ and ‘reading between the lines.’ Our platform technology is addressing some of healthcare’s biggest challenges—saving time, saving costs, and saving lives.

The Company’s product, the PURE EP™ Platform, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our cost reduction plan and associated workforce reduction or other cost-saving measures not reaching the targeted reduction of cash burn by 50%; (ii) the geographic, social, and economic impact of pandemics or worldwide health issues on BioSig’s ability to conduct its business and raise capital in the future when needed; (iii) BioSig’s inability to manufacture its products and product candidates on a commercial scale on its own, or in collaboration with third parties; (iv) difficulties in obtaining financing on commercially reasonable terms; (v) changes in the size and nature of BioSig’s competition; (vi) loss of one or more key executives or scientists; and (vii) difficulties in securing regulatory approval to market BioSig’s products and product candidates. For a discussion of other risks and uncertainties, and other important factors, any of which could cause BioSig’s actual results to differ from those contained in forward-looking statements, see BioSig’s filings with the Securities and Exchange Commission (“SEC”), including the section titled “Risk Factors” in BioSig’s Annual Report on Form 10-K, filed with the SEC on April 16, 2024. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise, except as required by law.

FAQ

How much did BioSig Technologies (BSGM) reduce its accounts payable in Q2 2024?

BioSig Technologies (BSGM) reduced its accounts payable by approximately $1.5 million during the second quarter of 2024.

What significant cost-saving measure did BioSig Technologies (BSGM) implement in July 2024?

BioSig Technologies (BSGM) terminated the office lease expense for their former headquarters in Westport, Connecticut, effective July 15, 2024, which was originally set to end on December 31, 2024.

What is BioSig Technologies' (BSGM) main product?

BioSig Technologies' main product is the PURE EP™ Platform, an FDA 510(k) cleared non-invasive class II device for cardiac signal visualization during ablation procedures.

What is BioSig Technologies' (BSGM) stock symbol and market?

BioSig Technologies trades under the stock symbol BSGM on the OTCQB market.